Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117975 | 1.00 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2CALM1CAMKK2CHRNB2 | |
| Hydrochloric Acid SCHEMBL7676026 | 0.99 | SMN1; SMN2 (0.45) | ALDH1A1SMN1; SMN2CALM1CAMKK2CHRNB2 | |
| Hydrochloric Acid SCHEMBL7676029 | 0.99 | SMN1; SMN2 (0.45) | ALDH1A1SMN1; SMN2CALM1CAMKK2CHRNB2 | |
| SCHEMBL10349809 | 0.84 | ALDH1A1 (0.51) | ALDH1A1AOC3HTR2A | |
| SCHEMBL18897543 | 0.80 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2CALM1CAMKK2AOC3 | |
| SCHEMBL4624693 | 0.79 | ALDH1A1 (0.70) | ALDH1A1SMN1; SMN2CALM1CAMKK2AOC3 | |
| SCHEMBL669922 | 0.79 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2CALM1CAMKK2AOC3 | |
| SCHEMBL8526677 | 0.79 | ALDH1A1 (0.70) | ALDH1A1SMN1; SMN2CALM1CAMKK2AOC3 | |
| SCHEMBL670608 | 0.79 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2CALM1CAMKK2AOC3 | |
| SCHEMBL670046 | 0.79 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2CALM1CAMKK2AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180235909-A1 | Use of 1-phenyl-3-dimethylaminopropane Compounds for Treating Rheumatoid Pain | GRUENENTHAL GMBH (DE) | 2018-08-23 | — | — | US | claimed |
| US-20170326079-A1 | Use of 1-phenyl-3-dimethylaminopropane Compounds for Treating Rheumatoid Pain | GRUENENTHAL GMBH (DE) | 2017-11-16 | — | — | US | claimed |
| EP-3069717-A1 | USE OF 1-PHENYL-3-DIMETHYLAMINOPROPANE COMPOUNDS FOR TREATING RHEUMATOID PAIN | Grünenthal GmbH (DE) | 2016-09-21 | — | — | EP | claimed |
| US-20100311842-A1 | Use of 1-Phenyl-3-dimethylamino-propane Compounds for Treating Neuropathic Pain | GRUENENTHAL GMBH (DE) | 2010-12-09 | — | — | US | claimed |
| US-20100280128-A1 | Use of 1-phenyl-3-dimethylaminopropane Compounds for Treating Rheumatoid Pain | GRUENENTHAL GMBH (DE) | 2010-11-04 | — | — | US | claimed |
| EP-2117525-A1 | USE OF 1-PHENYL-3-DIMETHYLAMINO-PROPANE COMPOUNDS FOR THE THERAPY OF NEUROPATHY PAIN | Grünenthal GmbH (DE) | 2009-11-18 | — | — | EP | claimed |
| US-20080269326-A1 | Use of 1-Phenyl-3-Dimethylamino-propane Compounds for Treating Neuropathic Pain | GRUENENTHAL GMBH (DE) | 2008-10-30 | — | — | US | claimed |
| WO-2008110323-A1 | USE OF 1-PHENYL-3-DIMETHYLAMINO-PROPANE COMPOUNDS FOR THE THERAPY OF NEUROPATHY PAIN | Grünenthal GmbH (DE) | 2008-09-18 | — | — | WO | claimed |
| EP-1438034-B1 | USE OF 1-PHENYL-3-DIMETHYLAMINOPROPANE COMPOUNDS FOR TREATING URINARY INCONTINENCE | GRUENENTHAL GMBH (DE) | 2008-07-30 | — | — | EP | claimed |
| EP-1429754-B1 | COMBINATION OF SELECTED OPIOIDS WITH MUSCARINE ANTAGONISTS FOR TREATING URINARY INCONTINENCE | GRUENENTHAL GMBH (DE) | 2008-01-16 | — | — | EP | claimed |
| EP-1507520-A1 | COMBINATION OF SELECTED OPIOIDS WITH OTHER ACTIVE SUBSTANCES FOR USE IN THE THERAPY OF URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2005-02-23 | — | — | EP | claimed |
| US-6841575-B2 | Use of 1-phenyl-3-dimethylaminopropane compounds for treatment of urinary incontinence | GRUENENTHAL GMBH (DE) | 2005-01-11 | — | — | US | claimed |
| US-20040242617-A1 | active at very low doses, therefore low side effect profile | GRUENENTHAL GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| EP-1438034-A2 | USE OF 1-PHENYL-3-DIMETHYLAMINOPROPANE COMPOUNDS FOR TREATING URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2004-07-21 | — | — | EP | claimed |
| EP-1429754-A1 | COMBINATION OF SELECTED OPIOIDS WITH MUSCARINE ANTAGONISTS FOR TREATING URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2004-06-23 | — | — | EP | claimed |
| WO-2004047823-A1 | COMBINATION OF SELECTED ANALGESICS AND COX-II INHIBITORS | Grünenthal GmbH (DE) | 2004-06-10 | — | — | WO | claimed |
| US-20040034105-A1 | Use of 1-phenyl-3-dimethylaminopropane compounds for treatment of urinary incontinence | GRUENENTHAL GMBH (DE) | 2004-02-19 | — | — | US | claimed |
| WO-2003099268-A1 | COMBINATION OF SELECTED OPIOIDS WITH OTHER ACTIVE SUBSTANCES FOR USE IN THE THERAPY OF URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2003-12-04 | — | — | WO | claimed |
| WO-2003024444-A1 | COMBINATION OF SELECTED OPIOIDS WITH MUSCARINE ANTAGONISTS FOR TREATING URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2003-03-27 | — | — | WO | claimed |
| WO-2002043715-A2 | USE OF 1-PHENYL-3-DIMETHYLAMINOPROPANE COMPOUNDS FOR TREATING URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2002-06-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242617-A1 | active at very low doses, therefore low side effect profile | OPRM1, OPRK1, OPRD1 | ALDH1A1 508/4885SMN1; SMN2 384/4885CALM1 1114/4885 |
| US-20080269326-A1 | Use of 1-Phenyl-3-Dimethylamino-propane Compounds for Treating Neuropathic Pain | PMP22, GAP43, IAPP | ALDH1A1 598/4885SMN1; SMN2 38/4885CALM1 1853/4885 |
| US-20040034105-A1 | Use of 1-phenyl-3-dimethylaminopropane compounds for treatment of urinary incontinence | PNMT, UROD, PDE3A | ALDH1A1 32/4885SMN1; SMN2 1703/4885CALM1 982/4885 |
| US-20180235909-A1 | Use of 1-phenyl-3-dimethylaminopropane Compounds for Treating Rheumatoid Pain | OPRK1, DRG1, OPRL1 | ALDH1A1 185/4885SMN1; SMN2 3414/4885CALM1 1604/4885 |
| US-20170326079-A1 | Use of 1-phenyl-3-dimethylaminopropane Compounds for Treating Rheumatoid Pain | OPRK1, DRG1, OPRL1 | ALDH1A1 185/4885SMN1; SMN2 3414/4885CALM1 1604/4885 |
| US-20100280128-A1 | Use of 1-phenyl-3-dimethylaminopropane Compounds for Treating Rheumatoid Pain | OPRK1, DRG1, OPRL1 | ALDH1A1 185/4885SMN1; SMN2 3414/4885CALM1 1604/4885 |
| US-20100311842-A1 | Use of 1-Phenyl-3-dimethylamino-propane Compounds for Treating Neuropathic Pain | PMP22, GAP43, IAPP | ALDH1A1 598/4885SMN1; SMN2 38/4885CALM1 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.